ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2214

Donor-Derived Fibrillary Glomerulonephritis in a Renal Allograft

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical


  • Jespersen, Tiana, University of California Davis, Sacramento, California, United States
  • Huang, Yihung, University of California Davis, Sacramento, California, United States
  • Alnimri, Muna, University of California Davis, Sacramento, California, United States
  • Jen, Kuang-Yu, University of California Davis, Sacramento, California, United States

Fibrillary glomerulonephritis (FGN) is a rare progressive renal disease that is defined by the presence of randomly oriented non-branching fibrils showing positive immunostaining for DnaJ homolog subfamily B member 9 (DNAJB9). Recurrent FGN in renal allografts have been described with an indolent course. We report a case of donor-derived FGN in a renal allograft.

Case Description

A 73-year-old female with history of end-stage renal disease (ESRD) due to anti-myeloperoxidase antibody-associated pauci-immune glomerulonephritis received a preemptive deceased donor renal transplant from a 62-year-old 79% Kidney Donor Profile Index female. The patient experienced slow graft function and nadir serum creatinine (Cr) of 1.7 mg/dL at 4 months post-transplant with subsequent Cr stabilizing in the 2.0-2.3 mg/dL range. Proteinuria mainly fluctuated between 1-2 g/g. Time-0 biopsy demonstrated mild mesangial widening/hypercellularity with rare glomerular capillary double contours. Ancillary studies revealed positive staining for DNAJB9 and kappa light chain-restriction, consistent with donor-derived FGN. 4-month surveillance biopsy showed similar findings. Background renal parenchyma showed moderate chronicity with prominent chronic vascular disease. At 10-months post-transplant, Cr remains at ~2 mg/dL and proteinuria remained in the 1-1.6 g/g range.


FGN carries a poor prognosis with nearly half of patients progressing to ESRD within a few years. A case series of recurrent FGN after kidney transplantation suggests a relatively benign clinical course including a single report of donor-derived FGN (from a living related donor) without proteinuria in the recipient. Our case shows a more severely afflicted allograft that resulted in persistent low-grade but stable proteinuria in the recipient. Suboptimal Cr was also observed following transplant as well, although the allograft had other factors such as chronicity and chronic vascular disease.